UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
April 25, 2024
ARVO 2024 Presentation Details:
Title: Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up
Posterboard Number: B0103
Date & Time:
Location: Exhibit Hall -
Presenter:
Title: Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing
Posterboard Number: B0391
Date & Time:
Location: Exhibit Hall -
Presenter:
Additional presentation details and abstracts are available on the ARVO 2024 website here.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investor Contact
jallaire@lifesciadvisors.com
Source: Unity Biotechnology, Inc.